New Frost & Sullivan analysis reveals that future winners will be those that can execute faster, industrialise innovation, and navigate mounting pricing and geopolitical pressures
LONDON, June 11, 2026 /PRNewswire/ -- Frost & Sullivan's latest analysis, Growth Opportunities in Global Pharmaceutical Industry, 2026, finds that the pharmaceutical industry is entering a period of profound transformation as affordability mandates, patent expiries, geopolitical fragmentation, and rapid technological advances reshape the foundations of value creation.
According to the study, traditional drivers of success are being replaced by a new set of competitive imperatives centred on execution excellence, supply resilience, AI-enabled operations, and the ability to commercialise increasingly complex therapeutic modalities at scale.